WHITE PAPER
Understanding the Safety Strategies and Regulatory Considerations of Drug Development in the JAPAC Region
Jan 17, 2024

If you are considering launching a drug program in the burgeoning JAPAC market, it is important to familiarize your team with regulatory nuances and safety initiatives across the region. IQVIA's white paper outlines the safety strategies and regulatory considerations of drug development in the Japan and Asia-Pacific (JAPAC) region. It explores the rapidly growing biopharma market, the distinct regulatory nuances of each country, and the role of technology in pharmacovigilance. The piece also highlights the adoption of International Council for Harmonization (ICH) guidelines in China and Japan, offering crucial insights for businesses planning to launch drug programs in this region.

Download and learn how IQVIA can help you navigate the compliance intricacies of the JAPAC region.

Related solutions

Contact Us